RT Journal Article
T1 Haploidentical transplantation in high-risk pediatric leukemia: A retrospective comparative analysis on behalf of the Spanish working Group for bone marrow transplantation in children (GETMON) and the Spanish Grupo for hematopoietic transplantation (GETH).
A1 Perez-Martinez, Antonio
A1 Ferreras, Cristina
A1 Pascual, Antonia
A1 Gonzalez-Vicent, Marta
A1 Alonso, Laura
A1 Badell, Isabel
A1 Fernandez Navarro, Jose Maria
A1 Regueiro, Alexandra
A1 Plaza, Mercedes
A1 Perez Hurtado, Jose Maria
A1 Benito, Ana
A1 Belendez, Cristina
A1 Couselo, Jose Miguel
A1 Fuster, Jose Luis
A1 Díaz-Almiron, Mariana
A1 Bueno, David
A1 Mozo, Yasmina
A1 Marsal, Julia
A1 Gomez Lopez, Alicia
A1 Sisinni, Luisa
A1 Diaz-de-Heredia, Cristina
A1 Diaz, Miguel Angel
K1 Graft Survival
K1 Graft vs Host Disease
K1 Hematologic Neoplasms
K1 Hematopoietic Stem Cell Transplantation
AB A total of 192 pediatric patients, median age 8.6 years, with high-risk hematological malignancies, underwent haploidentical stem cell transplantation (haplo-HSCT) using post-transplantation cyclophosphamide (PT-Cy), or ex vivo T cell-depleted (TCD) graft platforms, from January 1999 to December 2016 in 10 centers in Spain. Some 41 patients received an unmanipulated graft followed by PT-Cy for graft-vs-host disease (GvHD) prophylaxis. A total of 151 patients were transplanted with CD3-depleted peripheral blood stem cells (PBSCs) by either CD34+ selection, CD3+ CD19+ depletion, TCRαβ+ CD19+ depletion or CD45RA+ depletion, added to CD34+ selection for GvHD prophylaxis. The PBSCs were the only source in patients following ex vivo TCD haplo-HSCT; bone marrow was the source in 9 of 41 patients following PT-CY haplo-HSCT. Engraftment was achieved in 91.3% of cases. A donor younger than 30 years, and the development of chronic GvHD were positive factors influencing survival, whereas positive minimal residual disease (MRD) before transplant and lymphoid disease were negative factors. The probability of relapse increased with lymphoid malignancies, a donor killer-cell immunoglobulin-like receptor (KIR) haplotype A and positive MRD pretransplant. No difference was found in overall survival, disease-free survival or relapse incidence between the two platforms. Relapse is still of concern in both platforms, and it should be the focus of future efforts. In conclusion, both platforms for haplo-HSCT were effective and could be utilized depending on the comfort level of the center.
PB John Wiley & Sons
YR 2019
FD 2019-12-10
LK http://hdl.handle.net/10668/14922
UL http://hdl.handle.net/10668/14922
LA en
NO Pérez-Martínez A, Ferreras C, Pascual A, Gonzalez-Vicent M, Alonso L, Badell I, et al. Haploidentical transplantation in high-risk pediatric leukemia: A retrospective comparative analysis on behalf of the Spanish working Group for bone marrow transplantation in children (GETMON) and the Spanish Grupo for hematopoietic transplantation (GETH). Am J Hematol. 2020 Jan;95(1):28-37
DS RISalud
RD Apr 6, 2025